# Antimicrobial Susceptibility Test Market

> Antimicrobial susceptibility test market: USD 3.92 billion in 2025, 5.83% a year to 2035 as FDA STIC breakpoints and rapid blood-culture AST lift volumes.

Publisher: Douglas Insights  
Author: Douglas Insights Research Desk  
Report code: DI-HC-10693  
Published: 2026-10-08  
Last updated: 2026-10-08  
Next review: Apr 2027  
Page: https://www.douglasinsights.com/antimicrobial-susceptibility-test-market/

## Key figures

| Measure | Value | How it is built |
| --- | --- | --- |
| Market size · 2025 | $3.92 Bn | 268.4 million AST runs at an average USD 14.62 each give USD 3.92 billion. |
| Forecast · 2035 | $6.92 Bn | 410.9 million runs at about USD 16.83 each. |
| Revenue CAGR · 2026-2035 | 5.83% | Multiplicative volume and price legs. |
| Volume · 2035 | 410.9 million runs | 268.4 million runs compounding at 4.35%. |
| Leading segment | Automated AST panels and cards, 44.8% | USD 1.76 billion in 2025. |
| Fastest segment | Rapid phenotypic AST, 14.41% | USD 247.2 million to USD 949.9 million. |
| Fastest region | Asia Pacific, 7.94% | USD 926.1 million to USD 1.99 billion. |
| Market leader | bioMérieux, about 34.6% | Douglas Insights estimate; top three hold 69.6%. |
| Event | FDA STIC website, 13 Dec 2017 | Section 511A lets AST sponsors cite FDA-listed breakpoints. |

## Key takeaways

- 268.4 million antimicrobial susceptibility test runs at USD 14.62 each make a USD 3.92 billion market in 2025, rising to USD 6.92 billion by 2035 at 5.83% a year.
- Automated AST panels and cards earn USD 1.76 billion, 44.8% of value, because every placed analyser pulls proprietary consumables for a decade.
- Rapid phenotypic AST from positive blood cultures grows 14.41% a year to USD 949.9 million, yet stays about 32% the size of automated panels.
- bioMérieux, Waters (BD Phoenix) and Beckman Coulter hold about 69.6% of revenue by Douglas Insights estimate, with bioMérieux alone near 34.6%.
- Asia Pacific grows fastest at 7.94% a year, from USD 926.1 million to USD 1.99 billion, while North America leads at USD 1.52 billion.

Because Section 511A of the US Federal Food, Drug, and Cosmetic Act lets device makers cite the breakpoints that the US Food and Drug Administration (FDA) lists on its Susceptibility Test Interpretive Criteria (STIC) website, launched by [Federal Register notice on 13 December 2017](https://www.govinfo.gov/content/pkg/FR-2017-12-13/pdf/2017-26790.pdf), antimicrobial susceptibility test panels now track new drug cut-offs within months. The antimicrobial susceptibility test market covers the panels, cards, discs, gradient strips, microdilution plates, instruments and software that clinical laboratories use to tell clinicians which antibiotics will work against a cultured pathogen. Douglas Insights sizes it at USD 3.92 billion in 2025: 268.4 million antimicrobial susceptibility testing (AST) runs at an average USD 14.62 each. Revenue reaches USD 6.92 billion by 2035, a 5.83% annual pace built from 4.35% volume growth and 1.42% price growth. The study belongs to our [in-vitro diagnostics](https://www.douglasinsights.com/industry/healthcare/in-vitro-diagnostics/) coverage, and every step of the build follows the [Douglas Insights research methodology](https://www.douglasinsights.com/research-methodology/).

## Who supplies antimicrobial susceptibility test systems, and how concentrated is the competition?

Three suppliers hold about 69.6% of 2025 antimicrobial susceptibility test revenue, by Douglas Insights estimate: bioMérieux, the Phoenix franchise now inside Waters, and Beckman Coulter with MicroScan. Their lead rests on installed automated instruments, because every placed analyser locks in years of proprietary panel or card purchases.

bioMérieux leads with an estimated 34.6% share, or about USD 1.36 billion of antimicrobial susceptibility test sales. Its VITEK 2 card reader holds 60 cards, the XL version 120, and the company lists susceptibility menus covering up to 180 antimicrobials. bioMérieux bought Specific Diagnostics in 2022 and won FDA 510(k) clearance for the resulting VITEK REVEAL system on [21 June 2024](https://www.biomerieux.com/us/en/journalists/press-releases/vitek-reveal-fda-clearance-ast-system.html), with Gram-negative results from positive blood cultures in an average 5.5 to 6 hours. Group sales reached EUR 4.07 billion in 2025, yet its [27 February 2026 results](https://www.biomerieux.com/us/en/journalists/press-releases/2025-financial-results.html) booked a partial impairment of the REVEAL technology and a double-digit fall in China microbiology.

Waters now owns the BD Phoenix line after its Reverse Morris Trust combination with BD's biosciences and diagnostic solutions businesses closed. The Phoenix M50 instrument stacks two units in one footprint; its panels carry 85 antimicrobial dilution wells, and the Emerge panel 136 wells. Douglas Insights puts the franchise at 19.8% of antimicrobial susceptibility test revenue. Beckman Coulter follows at an estimated 15.2%, selling MicroScan panels on the DxM MicroScan WalkAway, often paired with the Bruker MALDI Biotyper for identification in its DxM Trio bundle.

Thermo Fisher Scientific takes about 9.7% through Sensititre broth microdilution plates, which it describes as the gold-standard method, with more than 300 antimicrobials available for custom plates. Bruker supplies matrix-assisted laser desorption/ionisation (MALDI) identification that sits upstream of almost every automated AST run. Q-linea of Sweden sells the FDA-cleared ASTar rapid platform. Accelerate Diagnostics, an early rapid-AST name, agreed to sell substantially all assets to Indaba Capital for a USD 36.9 million credit bid inside Chapter 11. The remaining 20.7% is spread across these challengers and regional disc makers.

| Company | AST platform | Douglas Insights share estimate, 2025 | Basis |
| --- | --- | --- | --- |
| bioMérieux | VITEK 2, VITEK REVEAL, ETEST | 34.6% | Group microbiology scale, installed VITEK base |
| Waters (BD Phoenix) | Phoenix M50, Phoenix panels | 19.8% | Installed Phoenix base, panel pull-through |
| Beckman Coulter | DxM MicroScan WalkAway | 15.2% | MicroScan panel installed base |
| Thermo Fisher Scientific | Sensititre, Oxoid discs | 9.7% | Broth microdilution plates, reference labs |
| Others (Q-linea and regional makers) | ASTar, discs, strips | 20.7% | Residual of the bottom-up build |

## Which antimicrobial susceptibility test product segment makes the money?

Automated AST panels and cards earn USD 1.76 billion, or 44.8% of 2025 antimicrobial susceptibility test revenue, because each placed VITEK, Phoenix or MicroScan analyser consumes a proprietary panel for every isolate. Rapid phenotypic AST from positive blood cultures grows fastest, at 14.41% a year.

| Segment | Share 2025 | Value 2025 (USD million) | Growth 2026-2035 | Value 2035 (USD million) |
| --- | --- | --- | --- | --- |
| Automated AST panels and cards | 44.8% | 1,758.0 | 5.31% | 2,949.3 |
| Disc diffusion and gradient strips | 17.9% | 702.4 | 2.74% | 920.4 |
| Broth microdilution MIC plates | 13.4% | 525.8 | 5.66% | 911.9 |
| AST instruments and software | 13.1% | 514.0 | 4.12% | 769.7 |
| Rapid phenotypic AST from positive blood cultures | 6.3% | 247.2 | 14.41% | 949.9 |
| Molecular resistance marker assays | 4.5% | 176.6 | 8.93% | 415.4 |

Automated AST panels and cards rise from USD 1.76 billion to USD 2.95 billion at 5.31%, since a 120-card VITEK 2 XL or a stacked Phoenix pair turns each new installation into a decade of consumable demand. Disc diffusion and gradient strips hold USD 702.4 million at 17.9%: cheap, flexible and standard in smaller laboratories, they grow only 2.74% as automation absorbs routine isolates. Broth microdilution MIC plates carry USD 525.8 million and grow 5.66%, as reference laboratories run minimum inhibitory concentration (MIC) work on new beta-lactam combinations before automated panels add them.

AST instruments and software total USD 514.0 million, 13.1% of value, growing 4.12% on replacement cycles and middleware upgrades. Molecular resistance marker assays, at USD 176.6 million, grow 8.93% as carbapenemase gene detection moves earlier in the workflow. Rapid phenotypic AST from positive blood cultures is the smallest phenotypic line at USD 247.2 million, yet climbs to USD 949.9 million by the end of the decade, because a 6-hour result lets sepsis teams change therapy the same day.

## Why are hospital laboratories buying more antimicrobial susceptibility tests every year?

Antimicrobial susceptibility test volumes grow 4.35% a year because resistance keeps rising, blood-culture workflows are accelerating and breakpoint revisions keep expanding panel menus. Douglas Insights splits that volume leg into four contributions worth 1.62, 1.18, 0.94 and 0.61 points.

Resistance itself adds 1.62 points. The World Health Organization (WHO) reported on [13 October 2025](https://www.who.int/news/item/13-10-2025-who-warns-of-widespread-resistance-to-common-antibiotics-worldwide) that about 1 in 6 laboratory-confirmed bacterial infections in 2023 resisted treatment, with resistance rising in over 40% of monitored pathogen and antibiotic pairs between 2018 and 2023 at 5% to 15% a year. Reporting countries in its Global Antimicrobial Resistance and Use Surveillance System (GLASS) grew from 25 in 2016 to 104 in 2023. Each newly reporting laboratory adds culture and antimicrobial susceptibility test volume, and each resistant isolate often triggers a second panel or a gradient strip confirmation.

Faster blood-culture results add 1.18 points. bioMérieux cites 11 million sepsis deaths a year worldwide, 1.3 million of them attributable to resistant bacteria, in its [21 June 2024 VITEK REVEAL clearance release](https://www.biomerieux.com/us/en/journalists/press-releases/vitek-reveal-fda-clearance-ast-system.html). Same-day AST from a positive bottle shifts sepsis therapy decisions by roughly a day, and our model finds about 2.5 rapid runs per 100 automated runs in 2025. Hospitals that buy a rapid system rarely drop the overnight panel, so the test count rises on both sides. A sepsis programme that adds rapid runs for 1,000 positive bottles a year still confirms most of them on its routine analyser, so one bloodstream isolate can generate two antimicrobial susceptibility test charges instead of one.

Menu expansion adds 0.94 points. FDA recognised the 36th edition of the Clinical and Laboratory Standards Institute (CLSI) M100 standard on its [STIC page updated 17 June 2026](https://www.fda.gov/drugs/development-resources/antibacterial-susceptibility-test-interpretive-criteria), and the 13 December 2017 website launch let sponsors cite those listed criteria in premarket filings. Q-linea added 93 bug and drug combinations on [16 April 2026](https://qlinea.com/mfn_news/q-linea-announces-fda-clearance-of-expanded-astar-blood-testing-menu/?ln=en), taking its ASTar Gram-negative menu to 215, roughly 75% more than its first panel. Every new drug that gains an FDA-recognised breakpoint becomes another well, and another reason to repeat antimicrobial susceptibility test runs.

Laboratory build-out in Asia Pacific, the Middle East and Latin America adds the final 0.61 points. Our model puts Asia Pacific volume growth near 6.3% a year as provincial hospitals add automated identification and susceptibility lines. Together the four contributions equal the 4.35% volume leg; the 1.42% price leg comes mainly from the shift toward rapid and MIC formats.

## Which headwinds slow antimicrobial susceptibility test revenue growth?

Three headwinds remove about 1.14 points from antimicrobial susceptibility test volume growth, by Douglas Insights estimate: China procurement pressure, flat laboratory budgets and the cost of failed rapid platforms. Without them the volume leg would run near 5.49% instead of 4.35%.

China pricing and procurement remove 0.48 points. bioMérieux reported 4% organic microbiology growth for 2025 but 6.3% excluding China, after a double-digit decline there, in its [27 February 2026 results release](https://www.biomerieux.com/us/en/journalists/press-releases/2025-financial-results.html). Volume-based purchasing pushes antimicrobial susceptibility test panel prices down and delays automated placements in county hospitals.

Flat laboratory budgets and staffing remove 0.37 points. A typical high-volume United States microbiology laboratory runs about 400,000 tests a year with an 8.2% positivity rate in BD's own workflow model, and adding a second AST platform needs bench space, validation time and technologists that many hospitals lack. Rapid platform economics remove 0.29 points: bioMérieux booked a partial impairment of VITEK REVEAL, and Accelerate Diagnostics went through Chapter 11 with a USD 36.9 million credit bid. Investors now demand proof of reimbursement before funding new rapid antimicrobial susceptibility test systems.

## Where do antimicrobial susceptibility test volumes grow fastest?

North America leads with USD 1.52 billion of 2025 antimicrobial susceptibility test revenue, 38.7% of the total, while Asia Pacific grows fastest at 7.94% a year on new hospital laboratories and rising resistance. Douglas Insights expects Asia Pacific to reach USD 1.99 billion by 2035.

North America grows 5.08% to USD 2.49 billion, carried by early rapid-AST adoption, the STIC breakpoint pipeline and the more than 2.8 million resistant infections a year in Centers for Disease Control and Prevention (CDC) threat estimates. Europe holds USD 1.11 billion, 28.4%, and grows 4.71% to USD 1.77 billion; EUCAST, the European Committee on Antimicrobial Susceptibility Testing, keeps tables free to use, so disc diffusion stays common there.

Asia Pacific starts at USD 926.1 million, 23.6%, and doubles to USD 1.99 billion because India and Southeast Asia are still automating and WHO places the South-East Asia region among the highest resistance burdens, at about 1 in 3 infections. Latin America adds USD 204.0 million, 5.2%, growing 6.37% to USD 378.3 million. The wildcard is the Middle East and Africa: USD 160.9 million, 4.1%, growing 6.13% to USD 291.7 million, with WHO reporting resistance above 70% to third-generation cephalosporins in the African Region and Q-linea already shipping ASTar instruments to Saudi Arabia.

| Region | 2025 (USD million) | Share | CAGR 2026-2035 | 2035 (USD million) |
| --- | --- | --- | --- | --- |
| North America | 1,518.6 | 38.7% | 5.08% | 2,492.6 |
| Europe | 1,114.4 | 28.4% | 4.71% | 1,765.7 |
| Asia Pacific | 926.1 | 23.6% | 7.94% | 1,988.3 |
| Latin America | 204.0 | 5.2% | 6.37% | 378.3 |
| Middle East and Africa | 160.9 | 4.1% | 6.13% | 291.7 |

## How much do laboratories pay per antimicrobial susceptibility test?

Laboratories pay an average USD 14.62 per antimicrobial susceptibility test run in 2025, by Douglas Insights estimate, rising to about USD 16.83 by 2035 at 1.42% a year. Bands run from a few dollars for discs to over USD 60 for rapid blood-culture runs.

| Format | Douglas Insights realised price band per run, 2025 | Main buyer |
| --- | --- | --- |
| Disc diffusion and gradient strips | USD 3 to USD 9 | Small and mid-size hospital laboratories |
| Automated AST panels and cards | USD 11 to USD 21 | Hospital laboratories |
| Broth microdilution MIC plates | USD 15 to USD 28 | Reference laboratories |
| Rapid phenotypic AST from positive blood cultures | USD 62 to USD 118 | Sepsis programmes in tertiary hospitals |
| Molecular resistance marker assays | USD 38 to USD 85 | Infection control and stewardship teams |

Instrument prices are recovered through reagent rental: our model spreads analyser and software revenue across seven years of runs, adding about USD 1.92 to the blended antimicrobial susceptibility test price. Mix, not list-price inflation, drives the 1.42% price leg: rapid runs cost about 5.6 times an automated card.

## Which tests and buyers does the antimicrobial susceptibility test market include?

The antimicrobial susceptibility test market includes six product groups worth USD 3.92 billion in 2025, sold to hospital laboratories, reference laboratories and pharmaceutical and research laboratories. Identification-only tests, blood culture bottles and antifungal drug sales sit outside the scope.

By application the model splits runs across bloodstream infections, urinary tract infections, respiratory infections and wound and other infections. Urine isolates supply the largest antimicrobial susceptibility test count, about 41% of runs in our model, while bloodstream isolates carry the highest value per run. Adjacent upstream spending is covered in our [Blood Culture Bottle Market](https://www.douglasinsights.com/blood-culture-bottle-market/) report, sample preparation in the [Magnetic Bead-based Nucleic Acid Extraction Market](https://www.douglasinsights.com/magnetic-bead-based-nucleic-acid-extraction-market/) study, and quality-control microbiology in the [Pharma Microbiology Testing Kits Market](https://www.douglasinsights.com/pharma-microbiology-testing-kits-market/) report.

## What breakpoint rules and standards govern antimicrobial susceptibility test menus?

Two breakpoint systems govern antimicrobial susceptibility test menus: the FDA STIC list in the United States, updated at least every six months, and EUCAST tables in Europe, now at version 16.1 from 24 June 2026. A panel sold without current breakpoints loses tenders.

Section 3044 of the 21st Century Cures Act, signed on 13 December 2016, added Section 511A and required FDA to open the STIC site within a year, which it did by [notice on 13 December 2017](https://www.govinfo.gov/content/pkg/FR-2017-12-13/pdf/2017-26790.pdf). The notice lets sponsors of antimicrobial susceptibility test devices rely on listed criteria for premarket authorisation, so a manufacturer no longer waits for each drug label change. The STIC page recognises CLSI M100 (36th edition, 2026), M45 (2015), M24 (2018), M24S (2023) and M43-A (2011), with listed exceptions.

The consequence is commercial. Q-linea describes its [expanded ASTar panel](https://qlinea.com/mfn_news/q-linea-announces-fda-clearance-of-expanded-astar-blood-testing-menu/?ln=en) as conforming to the latest FDA breakpoints, and bioMérieux holds CE marking for VITEK REVEAL under the In Vitro Diagnostic Medical Devices Regulation (IVDR) for the instrument. Douglas Insights counts five recognised CLSI documents and two EUCAST table sets in 2026, and each revision is a reason for laboratories to re-verify, and often re-buy, antimicrobial susceptibility test panels.

## What happens to antimicrobial susceptibility test revenue in slower and faster cases to 2035?

Antimicrobial susceptibility test revenue lands between USD 5.66 billion and USD 8.33 billion in 2035 across our three cases, with USD 6.92 billion as the base. Rapid-AST adoption and China procurement are the two swing factors.

| Case | Volume growth | Price growth | Revenue CAGR | 2035 value |
| --- | --- | --- | --- | --- |
| Slower | 2.90% | 0.80% | 3.72% | USD 5.66 billion |
| Base case | 4.35% | 1.42% | 5.83% | USD 6.92 billion |
| Faster | 5.60% | 2.10% | 7.82% | USD 8.33 billion |

The slower case assumes China volume-based purchasing spreads to Southeast Asia and that more rapid platforms follow REVEAL into write-downs, cutting volume growth to 2.90% and price growth to 0.80%. The faster case assumes STIC updates keep adding new beta-lactam combinations each half-year, as the 13 December 2017 [Federal Register notice](https://www.govinfo.gov/content/pkg/FR-2017-12-13/pdf/2017-26790.pdf) allows, and that same-day blood-culture AST becomes standard in tertiary hospitals, lifting volume to 5.60% and price to 2.10%.

One extra point of annual volume growth adds about USD 692.1 million to the 2035 antimicrobial susceptibility test figure. Published forecasts sit between 5.1% and 8.8% a year; our 5.83% falls in the lower half, because we net out the China decline and treat rapid platforms as additive only where hospitals keep paying for them.

## Douglas Exclusive: the Same-Shift AST Index

The Same-Shift AST Index is a Douglas Insights model, built from 14 inputs: four published turnaround times and the 2025 values and growth rates of five test segments. It measures the share of antimicrobial susceptibility test consumable spending that returns a result inside one 8-hour laboratory shift.

The four turnaround inputs are 6 to 8 hours for VITEK 2, 5.5 to 6 hours for VITEK REVEAL, about 6 hours for ASTar and 6 to 11 hours for BD Phoenix carbapenemase-producing organism (CPO) detection. Our model assigns a same-shift weight of 0.58 to automated AST panels and cards, 0.92 to rapid blood-culture runs, 0.85 to molecular marker assays and zero to disc diffusion and MIC plates, which our model treats as overnight reads. Instrument revenue is excluded, leaving USD 3.41 billion of 2025 consumable spend.

The index reads 41.0 in 2025 and 47.8 in 2035. In plain terms, 41.0% of antimicrobial susceptibility test consumable dollars already buy a same-shift answer, and the 6.8-point gain over the decade comes almost entirely from rapid blood-culture runs growing 14.41% a year. The finding: speed is spreading, but overnight methods still hold more than half of the spend by 2035.

| Year | Consumable spend (USD million) | Same-Shift AST Index |
| --- | --- | --- |
| 2025 | 3,410.0 | 41.0 |
| 2035 | 6,146.9 | 47.8 |

## Can rapid blood-culture AST overtake overnight antimicrobial susceptibility test panels?

No, not by 2035: rapid phenotypic AST reaches USD 949.9 million, about 32% of the USD 2.95 billion automated panel segment. Douglas Insights expects rapid systems to sit beside overnight antimicrobial susceptibility test panels rather than replace them.

Rapid runs cost about 5.6 times a standard card, and laboratories still confirm many results on their existing VITEK, Phoenix or MicroScan lines. bioMérieux's impairment of REVEAL, Accelerate's credit-bid sale and Q-linea's 215-combination menu show the same pattern: menus are now broad enough, but reimbursement for a faster antimicrobial susceptibility test remains thin.

## How the model reaches 268.4 million antimicrobial susceptibility test runs: what are the checks?

The model multiplies 268.4 million antimicrobial susceptibility test runs by USD 14.62 to reach USD 3.92 billion in 2025. It builds five regional models and draws on 14 sourced inputs plus 5 published growth forecasts.

Runs are built from culture positivity, isolates per positive culture and panels per isolate in each country model; price comes from the segment bands above, weighted by 2025 run mix. Volume compounds at 4.35% to 410.9 million runs by 2035 and price at 1.42% to USD 16.83, giving USD 6.92 billion. Cross-check one: the top-three share build implies bioMérieux AST sales of USD 1.36 billion, about 30% of its EUR 4.07 billion group sales at our assumed USD 1.13 per euro. Cross-check two: published 2025 market sizes run from USD 4.13 billion to USD 4.21 billion, within 7.3% of our USD 3.92 billion, which excludes identification-only products.

## What should buyers of antimicrobial susceptibility test platforms watch in 2027?

Watch three signals in 2027: the next two STIC updates, bioMérieux's China microbiology trend after its double-digit 2025 fall, and whether Waters invests in the Phoenix line. Each moves the antimicrobial susceptibility test forecast by a measurable amount.

A STIC update that recognises a new CLSI M100 edition without exceptions would support our faster menu path. A China recovery to mid-single-digit growth would add roughly 0.3 points to volume. Douglas Insights calculates that a 1-point rise in price growth alone would lift 2035 revenue by about USD 0.71 billion, slightly more than the USD 692.1 million from volume, so platform pricing under Waters ownership deserves as much attention as test counts.

## Market by segment

| Segment | Share | Value |
| --- | --- | --- |
| Automated AST panels and cards | 44.8% | $1,758.0 Mn |
| Disc diffusion and gradient strips | 17.9% | $702.4 Mn |
| Broth microdilution MIC plates | 13.4% | $525.8 Mn |
| AST instruments and software | 13.1% | $514.0 Mn |
| Rapid phenotypic AST from positive blood cultures | 6.3% | $247.2 Mn |
| Molecular resistance marker assays | 4.5% | $176.6 Mn |

## Market by region (USD million)

| Region | 2025 | 2026 | 2035 | CAGR 2026-2035 |
| --- | --- | --- | --- | --- |
| Global | 3,924 | 4,152.8 | 6,916.6 | 5.83% |
| North America | 1,518.6 | 1,595.7 | 2,492.6 | 5.08% |
| Europe | 1,114.4 | 1,166.9 | 1,765.7 | 4.71% |
| Asia Pacific | 926.1 | 999.6 | 1,988.3 | 7.94% |
| Latin America | 204 | 217 | 378.3 | 6.37% |
| Middle East and Africa | 160.9 | 170.8 | 291.7 | 6.13% |

## Dataset

| Series | Value | Unit |
| --- | --- | --- |
| Market size 2025 | 3,924 | USD million |
| Market size 2035 | 6,916.6 | USD million |
| Revenue CAGR 2026-2035 | 5.83 | percent |
| Volume CAGR 2026-2035 | 4.35 | percent |
| Price per AST run CAGR 2026-2035 | 1.42 | percent |

## Frequently asked questions

### How many antimicrobial susceptibility test runs did laboratories perform in 2025?

268.4 million runs, by Douglas Insights estimate, at an average USD 14.62 each, giving USD 3.92 billion of 2025 revenue. Volume grows 4.35% a year to 410.9 million runs by 2035.

### What will antimicrobial susceptibility testing be worth in 2035?

USD 6.92 billion in the base case, up from USD 3.92 billion in 2025 at 5.83% a year. The slower case gives USD 5.66 billion and the faster case USD 8.33 billion.

### Why does the FDA STIC website matter to AST panel makers?

13 December 2017 is when FDA opened the STIC website under Section 511A, letting sponsors cite listed breakpoints in premarket filings, so antimicrobial susceptibility test panels can add new drug cut-offs within months instead of waiting for label changes.

### How concentrated is the AST supplier base?

69.6% of 2025 revenue sits with three suppliers, by Douglas Insights estimate: bioMérieux at 34.6%, the BD Phoenix line now owned by Waters at 19.8%, and Beckman Coulter at 15.2%. Thermo Fisher Scientific adds about 9.7%.

### Is rapid blood-culture AST replacing overnight panels?

USD 949.9 million is where rapid phenotypic AST lands in 2035, growing 14.41% a year, still only about 32% of the USD 2.95 billion automated panel segment. Rapid systems add to overnight panels rather than replace them.

### What does a laboratory pay for one AST run?

USD 14.62 on average in 2025, by Douglas Insights estimate, rising to USD 16.83 by 2035. Discs and strips cost USD 3 to USD 9, automated cards USD 11 to USD 21, and rapid blood-culture runs USD 62 to USD 118.

### Which part of the world adds AST capacity fastest?

7.94% a year in Asia Pacific, the fastest regional rate, taking it from USD 926.1 million in 2025 to USD 1.99 billion by 2035 as hospitals automate and resistance stays high. North America still leads at USD 1.52 billion.

### What does the Same-Shift AST Index show?

41.0 in 2025 and 47.8 in 2035: the share of antimicrobial susceptibility test consumable spending that returns a result inside an 8-hour shift. The Douglas Insights model uses 14 inputs and finds overnight methods still hold over half of spend.

## Sources

- [US Federal Register / FDA, 21st Century Cures Act: Announcing the Establishment of the Susceptibility Test Interpretive Criteria Website](https://www.govinfo.gov/content/pkg/FR-2017-12-13/pdf/2017-26790.pdf)
- [US FDA, Antibacterial Susceptibility Test Interpretive Criteria](https://www.fda.gov/drugs/development-resources/antibacterial-susceptibility-test-interpretive-criteria)
- [bioMérieux, VITEK REVEAL FDA 510(k) clearance](https://www.biomerieux.com/us/en/journalists/press-releases/vitek-reveal-fda-clearance-ast-system.html)
- [bioMérieux, 2025 financial results](https://www.biomerieux.com/us/en/journalists/press-releases/2025-financial-results.html)
- [Q-linea, FDA clearance of expanded ASTar blood testing menu](https://qlinea.com/mfn_news/q-linea-announces-fda-clearance-of-expanded-astar-blood-testing-menu/?ln=en)
- [World Health Organization, WHO warns of widespread resistance to common antibiotics worldwide](https://www.who.int/news/item/13-10-2025-who-warns-of-widespread-resistance-to-common-antibiotics-worldwide)
- [bioMérieux, VITEK 2 product page](https://www.biomerieux.com/corp/en/our-offer/clinical-products/vitek-2.html)
- [BD, BD Phoenix M50 instrument](https://www.bd.com/en-us/products-and-solutions/products/product-families/bd-phoenix-m50-instrument)
- [Thermo Fisher Scientific, Antimicrobial susceptibility testing](https://www.thermofisher.com/us/en/home/clinical/clinical-microbiology/antimicrobial-susceptibility-testing.html)
- [Beckman Coulter, Microbiology products](https://www.beckmancoulter.com/products/microbiology)
- [EUCAST, Clinical breakpoints](https://www.eucast.org/clinical_breakpoints)

## How to cite

Douglas Insights, "Antimicrobial Susceptibility Test Market", DI-HC-10693, updated 2026-10-08, https://www.douglasinsights.com/antimicrobial-susceptibility-test-market/